Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Tiger “Is this good for us?” Good question! I think it is. Obviously RUA isn’t the only polymer producer with an eye on the biological implant market. They’re playing catch up to a certain extent with others already more established in this part of the medical devices industry.
But if they have developed a polyurethane with the ideal properties of prolonged life expectancy and no side effects ( thrombus, calcification, etc) then I think we’re onto a winner.
“ RUA Structural Heart has the opportunity to transform the global treatment of heart disease by delivering a synthetic heart valve that will be durable, so reducing the need for future replacement, and should not require lifelong drug treatment. As well as these clinical advantages, the manufacturing costs of a synthetic valve are expected to be considerably less than those of current valve technology making this a potentially disruptive advance in heart valve surgery.”
If other polymers match the life expectancy and safety profiles of the RUA product, manufacturing cost will determine which plastic is used. Simple economics. It looks like a polyurethane is easier and cheaper to use as a PHV base material. This is good for us.
Also worth remembering the bench top PHV tests RUA have been doing will still be ongoing. So they will be able to update the market with the results of this. Way beyond the 400,000,000 cycles - if memory serves - expected as part of the standard trial process for a new PHV.
Polymeric Heart Valves will replace mechanical and biological replacements:
https://www.mdpi.com/1422-0067/24/4/3963
In support of Tiger:
“ Rigorous testing
Both new valves are going through rigorous testing. Replacement heart valves are subject to International Organisation for Standardisation (ISO) standards, just like A4 paper and agricultural machinery. Currently, the ISO standard says: “There is, as yet, no heart valve substitute which can be regarded as ideal.”
It stipulates that a replacement valve must last 200 million heartbeats – about five years. Dr Moggridge is aiming for 400 million, or 10 years, as a minimum.
How can you test a heart valve outside the human body? You can use a homemade pulse duplicator (where water and glycerol flow through the valve to imitate blood) and then a durability tester. Dr Moggridge’s team have a new durability tester, costing £50,000 and funded by a BHF grant. “The tester can go at 30 times normal speed and test six valves at the same time,” he says. “It means we can simulate five years of use in six months.””
Agree Bella. Did AS jump or was he pushed? Can’t help thinking he’s been a hindrance to the development of the company. Still thinking it’s his personal plaything, and negotiating with BP from this position. Have BP had a quiet word? I agree big news is now more likely in the short - medium term.
An overview of the state of play in development of polymeric heart valves. A bit about the competition out there.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034107/
That dilution must have hurt. Been burnt by Avacta doing something similar.
Hope a post from a FNB / FNI is okay? 62,000,000 shares in circulation, 60% of these in ‘sticky hands’. This broker note suggests an mcap of £120,000,000. It’s worth reading, especially the analysis of the safety concerns re synthetic heart valves.
https://www.equitydevelopment.co.uk/hubfs/RUA%20Life%20Sciences%20plc%20-%2026%20July%202023%20note.pdf
Touk, it’s not a dilution that’s taking place. That would mean the the mass of drug has remained the same and blood volume has increased.
So the Pt1/2 of AVA6000 is going to be caused by its breakdown at the TME (good), breakdown throughout at non cancer sites (bad), and clearance of AVA6000 by kidneys or liver (good as long as no toxicity). All drugs have to be removed from the body - one way or another. So if the t1/2 is mainly because of FAP breakdown of AVA6000 at the TME, this is actually a good thing.
Earl - thanks for the heads-up on GST.
I’m officially 🤡 of the day. You’re all absolutely right, it is main market. Sorry!
A criticism of AIM, not GST.
I hope the market can, for once, allow some good news to add sustained value to a company. Sick of SPs falling back to no gain after supportive RNSs. Ignore the spike, but at least a sustained > 10% rise would be reasonable.
Can I ask for some help please? Are there any Brokers’ Notes about GST out there? Damned if I can find one! I’m quite happy for them to DYOR for me…
I’ve been very very badly burned by a fintech promising the world. Every RNS / comms deadline missed.
GST quietly getting the ducks lined up, and cats hearded together, ready for a coordinated launch coinciding with a central gov announcement re crypto works for me.
I’m very new to GST and this BB.
OH THANK GOD… sensible discussion, and anyone suggesting caution with expectations isn’t shot down in flames as a fudster.
🙏
GLA.
Once an entity has bought 30% of the shares in a company they must declare if they are intending to takeover that company or not. If not, they are not able to launch a takeover bid for a defined period. Possibly 6 months?
All set out here:
https://www.thetakeoverpanel.org.uk/
Nothing to stop secret talks being held, then a recommendation, or not, to accept the offer.
Wyndrum: that’s an excellent, thoughtful, post.
NYsize: you’re right, no point in moaning. It’s just so frustrating at present. But it doesn’t help or change anything.
I’m putting the pitchfork back in the shed.
GLA.
NYsize makes a very important comment about the state of the market. AIM is in terminal decline. I hope the link works. We need a CEO who can manage this very turbulent financial environment, whilst a CSO looks after the science - great post BV.
I hear what NYsize says about turning on AS. But likewise business is about evaluation and re-evaluation. Maybe AS is the best CEO? But it’s also fair to question that as the company evolves, and market’s significantly change, is there someone better suited to lead Avacta forward?
https://www.cityam.com/is-the-london-stock-exchanges-aim-in-terminal-decline/
Simple question. Is AS the best CEO Avacta could have. Avoiding ad hominem insults against him, he’s doing the best he can with a pure science background. He’s a scientist. Shouldn’t there be a Pharma trained businessperson running the company?